CapitolRadar tracks every publicly disclosed BIIB trade by US congress members and corporate insiders: 42 disclosed trades (21 buys, 21 sells) by 4 tracked traders, from 2018-10-29 to 2026-09-24. Updated daily from official filings.
Want a ping when Congress buys BIIB? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Biogen Inc. (BIIB) — Healthcare · Drug Manufacturers - General, market cap about $34.8B.
CapitolRadar analysis
42 trades split evenly between buys and sells
42 tracked BIIB trades comprise 21 buys and 21 sells by four distinct traders from October 29, 2018 through September 24, 2026. The equal transaction count shows no overall directional imbalance across the full disclosed period, although trade counts do not indicate the relative dollar size of purchases and sales. The sample is small—four traders—and the activity spans nearly eight years, so the aggregate split may obscure changes in trading patterns over time.
5 trades make 2026 Q3 the busiest listed quarter
5 trades were recorded in 2026 Q3, with one buy and therefore four sells. Among the other quarters provided, 2024 Q1 had four trades split between two buys and two sells, while 2023 Q4 had three trades, including two buys. Both trades in 2023 Q3 were sales, as was the single trade in 2023 Q2. The lone 2024 Q3 trade was also a sale, while the single trades in 2024 Q4 and 2025 Q3 were buys. These quarterly observations are small samples, and the listed quarters do not represent every quarter within the full tracking period.
17 of 21 buys came from Ro Khanna
17 buys are attributed to Ro Khanna, whose latest listed purchase was September 4, 2026. Josh Gottheimer accounts for the other four buys, with his latest dated January 10, 2022. Together, the two named buyers account for all 21 tracked BIIB purchases. Both also bought ADI, GOOGL, FCX, SNDK, MSFT and AMD, but this overlap only identifies shared buying activity and does not establish a reason for the trades.
Disclosures may appear up to 45 days after a transaction, so the record is not necessarily real time. Reported transaction amounts are generally disclosed as ranges, making amount-based values estimates; no amount ranges are provided here. Those timing and valuation limits, combined with only four tracked traders, constrain broader conclusions.
Analysis written from the tracked record on 2026-10-12; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 5 | 1 | 4 |
| 2025 Q3 | 1 | 1 | 0 |
| 2024 Q4 | 1 | 1 | 0 |
| 2024 Q3 | 1 | 0 | 1 |
| 2024 Q1 | 4 | 2 | 2 |
| 2023 Q4 | 3 | 2 | 1 |
| 2023 Q3 | 2 | 0 | 2 |
| 2023 Q2 | 1 | 0 | 1 |
Who is buying BIIB?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Ro Khanna | 17 | 2026-09-04 | — |
| Josh Gottheimer | 4 | 2022-01-10 | — |
Disclosed trades in BIIB
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-24 | Maria Elvira Salazar | sell | $1,001 - $15,000 | — |
| 2026-09-11 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2026-09-04 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2026-08-18 | Kevin Hern | sell | $1,001 - $15,000 | — |
| 2026-08-17 | Kevin Hern | sell | $1,001 - $15,000 | — |
| 2025-08-26 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-11-15 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-09-09 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2024-03-25 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2024-03-20 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2024-02-13 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-01-10 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-11-03 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-10-10 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-10-02 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-09-06 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-08-29 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-04-10 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-02-10 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-01-09 | Ro Khanna | sell | $1,001 - $15,000 | — |
These buyers also bought
Other stocks the tracked buyers of BIIB disclosed buying in the last six months: AMD (2) · MSFT (2) · ADI (2) · GOOGL (2) · SNDK (2) · RSG (2).
About Biogen Inc.
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selec…
Frequently asked questions
Which politicians bought BIIB most?
Ro Khanna leads with 17 disclosed buys, followed by Josh Gottheimer.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.